Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma
The purpose of this study is to confirm the safety and efficacy of Apatinib as the Second-line Therapy in Malignant Melanoma.
Malignant Melanoma
DRUG: Apatinib
Progression-free Survival (PFS), From date of randomization until the date of first documented progression or date of death from any cause, up to 2 year
Objective Response Rate (ORR), From date of randomization until the date of death from any cause, up to 1 year|Disease Control Rate (DCR), Defined as the proportion of patients with a documented complete response, partial response, and stable disease (CR + PR + SD) based on RECIST 1.1., up to 1 year|Overall survival(OS), From date of randomization until the date of death from any cause, up to 2 year
Melanoma is a malignant tumor caused by hyperplasia of abnormal melanoma cells.Most of the adults above 30 years of age occur in the skin, mucosa and internal organs. The investigators designed the study to explore the possibility of apatinib as the Second-line Therapy in Malignant Melanoma.